Systematic review compares shorter antitubercular regimens and 9 months of Isoniazid in children, indicating similar safety outcomes and treatment completion rates.
Shorter rifamycin-containing regimens for pediatric TBI probably increase treatment completion and have similar safety outcomes, with no important difference in development of TB disease compared with the standard regimen. These findings support current guideline recommendations that favor shorter regimens in children.
No takes yet. Share an insight, caveat, or question.
Kosenko et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: